Amisodin

PRG Science & Technology Co., Ltd. · Phase 1 active Small molecule Quality 0/100

Amisodin is an investigational drug developed by PRG Science & Technology Co., Ltd. It is currently in Phase 1 clinical trials for Amyotrophic Lateral Sclerosis (ALS). No FDA label exists, and the drug's safety and efficacy are under evaluation.

At a glance

Generic name	Amisodin
Sponsor	PRG Science & Technology Co., Ltd.
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Sub (Phase 1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Amisodin CI brief — competitive landscape report
Amisodin updates RSS · CI watch RSS
PRG Science & Technology Co., Ltd. portfolio CI